Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits) should be enrolled in the study.~* A Filipino male or female aged at least 6 weeks at the time of the first vaccination.~* Written informed consent obtained from the parent or guardian of the subject.~Exclusion Criteria:~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* Any history of chronic gastrointestinal disease including any uncorrected congenital malformation of the GI tract.~* Any contraindications as stated in the Prescribing Information.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 24 Weeks
- Healthy Volunteers: t

Study Arms:
- Cohort Group (Type: None): Subjects received two oral doses of the Rotarix vaccine at the age of 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).